Related Experiment Video
Updated: Aug 16, 2026
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer
Maija Wolf1, Henrik Edgren, Aslaug Muggerud
1Medical Biotechnology, VTT Technical Research Centre of Finland and University of Turku, FIN-20520 Turku, Finland. maija.wolf@vtt.fi
Abstract:
Gene mutations play a critical role in cancer development and progression, and their identification offers possibilities for accurate diagnostics and therapeutic targeting. Finding genes undergoing mutations is challenging and slow, even in the post-genomic era. A new approach was recently developed by Noensie and Dietz to prioritize and focus the search, making use of nonsense-mediated mRNA decay (NMD) inhibition and microarray analysis (NMD microarrays) in the identification of transcripts containing nonsense mutations. We combined NMD microarrays with array-based CGH (comparative genomic hybridization) in order to identify inactivation of tumor suppressor genes in cancer. Such a "mutatomics" screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene. Up to 8% of metastatic uncultured prostate cancers also showed mutations of this gene whose loss of function may confer loss of tissue architecture. NMD microarray analysis could turn out to be a powerful research method to identify novel mutated genes in cancer cell lines, providing targets that could then be further investigated for their clinical relevance and therapeutic potential.
Insights
This study introduces a novel "mutatomics" screening method combining NMD microarrays and CGH to identify cancer-driving gene mutations. The approach successfully identified inactivating mutations in the EPHB2 gene in prostate cancer, highlighting its potential for discovering new therapeutic targets.
Area of Science:
- Cancer genomics
- Molecular oncology
- Gene mutation analysis
Background:
- Gene mutations are crucial in cancer development, necessitating efficient identification methods for diagnostics and therapeutics.
- Current methods for identifying gene mutations are slow and challenging, even in the post-genomic era.
Purpose of the Study:
- To develop and apply a novel screening approach, termed "mutatomics", for identifying inactivating mutations in tumor suppressor genes in cancer.
- To combine nonsense-mediated mRNA decay (NMD) microarrays with array-based comparative genomic hybridization (CGH) for enhanced mutation detection.
Main Methods:
- Utilized NMD microarrays, which leverage NMD inhibition, to identify transcripts with nonsense mutations.
- Integrated NMD microarrays with array-based CGH to detect gene inactivation, specifically targeting tumor suppressor genes.
- Applied this combined approach to screen prostate cancer cell lines.
Main Results:
- The "mutatomics" screening successfully identified inactivating mutations in the EPHB2 gene in prostate cancer cell lines.
- Mutations in the EPHB2 gene were also found in up to 8% of metastatic, uncultured prostate cancers.
- Loss of EPHB2 function may lead to the disruption of tissue architecture.
Conclusions:
- NMD microarray analysis, when combined with CGH, is a powerful method for discovering novel mutated genes in cancer.
- The identified EPHB2 gene mutations represent potential targets for further clinical investigation and therapeutic development in prostate cancer.
More Related Videos
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
02:34DNA Microarrays